Head-to-head · free

Arbutus Biopharma Corp vs Baxter International Inc.

ABUS vs BAX — return on capital, cash generation, margins and balance sheet side by side.

ABUS

3 / 6

measures where ABUS leads

BAX

3 / 6

measures where BAX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureABUS · FY2025BAX · FY2025
Revenue$14.1M$11.2B
Net income(33.5M)(957.0M)
Revenue growth (yearly, multi-year)6.4%-3.2%
Free cash flow(39.6M)—
Free cash flow margin-281.5%—
Net cash / (debt)——
ROIC——
Return on equity-38.5%-14.6%
Gross margin—30.1%
Operating margin-192.1%1.6%
Net debt / EBITDA0.48x11.16x

Figures are as reported by each company; latest fiscal year shown.

Where Arbutus Biopharma Corp's cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABUS profile →

Where Baxter International Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full BAX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons